Reducing body myopathy associated with the LIM2 p.(His123Arg) FHL1 variant

Leila Darki1, Arash Jalali-Sohi1, Samuel Guzman2

  • 1Neuromuscular Division, Department of Neurology of the University of Southern California Keck School of Medicine, Los Angeles, CA, United States.

Insights

Reducing body myopathy (RBM) is a rare genetic muscle disorder. This case highlights a pathogenic FHL1 gene variant causing progressive muscle weakness and contractures in a young female.

Area of Science:

  • Neurology
  • Genetics
  • Muscle Biology

Background:

  • Reducing body myopathy (RBM) is a rare neuromuscular disorder characterized by specific protein aggregates within muscle fibers.
  • Mutations in the FHL1 gene are a known cause of RBM, presenting with variable clinical severity.
  • The spectrum of RBM ranges from severe infantile forms to adult-onset progressive muscle weakness.

Observation:

  • A 17-year-old female presented with progressive muscle weakness and contractures.
  • Muscle biopsy revealed atrophic muscle fibers containing characteristic menadione nitroblue tetrazolium (NBT)-positive reducing bodies.
  • Electrophysiological studies supported a myopathic process.

Findings:

  • Genetic analysis identified a variant in the FHL1 gene (p.His123Arg).
  • Initially classified as a variant of uncertain significance, this FHL1 variant was subsequently reclassified as pathogenic.
  • This pathogenic variant is located at a known mutation hotspot for RBM.

Implications:

  • This case expands the understanding of FHL1-associated RBM phenotypes.
  • Accurate genetic classification is crucial for diagnosing and managing rare myopathies.
  • Further research into FHL1 variants may elucidate genotype-phenotype correlations in RBM.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
102
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.1K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.1K
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
16.5K